Silo Pharma initiates pharmacokinetic, tolerability study for SP-26
Silo Pharma (SILO) announced the initiation of a pharmacokinetic and tolerability study in partnership with its contract research organization, ...
Business Insider15h
Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia
The study is designed to assess the pharmacokinetics of Silo’s dissolvable ketamine-based injectable implant, SP-26, in a minipig model. SP-26 is being developed as a self-administered, non-opioid ...